Ribavirin gel - Nanjing EffecttPharm Drug Development Corporation

Drug Profile

Ribavirin gel - Nanjing EffecttPharm Drug Development Corporation

Latest Information Update: 06 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanjing University
  • Developer Nanjing EffecttPharm Drug Development Corporation
  • Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
  • Mechanism of Action Nucleic acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Eye disorders

Most Recent Events

  • 01 Jul 2016 Clinical trials in Eye disorders in China (Ophthalmic) prior to July 2016
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top